We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

433 hedge funds and large institutions have $3.52B invested in CRISPR Therapeutics in 2025 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 127 increasing their positions, 101 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 60

60% more capital invested

Capital invested by funds: $2.2B → $3.52B (+$1.32B)

31% more call options, than puts

Call options by funds: $244M | Put options by funds: $186M

26% more repeat investments, than reductions

Existing positions increased: 127 | Existing positions reduced: 101

9% more funds holding

Funds holding: 396 → 433 (+37)

8.4% more ownership

Funds ownership: 75.39% → 83.79% (+8.4%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
433
Holders Change
+37
Holders Change %
+9.34%
% of All Funds
5.7%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
101
Increased
127
Reduced
101
Closed
60
Calls
$244M
Puts
$186M
Net Calls
+$58.2M
Net Calls Change
+$37.5M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$134M
2
OAG
Orbis Allan Gray
Bermuda
+$46.5M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$39.7M
4
State Street
State Street
Massachusetts
+$33.3M
5
UBS Group
UBS Group
Switzerland
+$29.9M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$38.2M
2
Morgan Stanley
Morgan Stanley
New York
-$30.5M
3
BBA
Baker Bros. Advisors
New York
-$22.3M
4
Millennium Management
Millennium Management
New York
-$19.9M
5
Capital International Investors
Capital International Investors
California
-$18.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
NSG
426
Nalls Sherbakoff Group
Tennessee
$146 -$155 -4 -57%
RF
427
Robbins Farley
New Hampshire
$146 – – –
JFA
428
JNBA Financial Advisors
Minnesota
$98 – – –
NB
429
NBT Bank
New York
$97 – – –
T
430
Transce3nd
Texas
$97 – – –
CWA
431
Carolina Wealth Advisors
South Carolina
$49 +$39 +1 New
WFI
432
West Family Investments
California
$49 +$1.37M +35,500 New
VWM
433
Valley Wealth Managers
New Jersey
$11 – – –
BBA
434
Baker Bros. Advisors
New York
– -$22.3M -654,099 Closed
Marshall Wace
435
Marshall Wace
United Kingdom
– -$13.4M -393,295 Closed
TCM
436
Tang Capital Management
California
– -$9.07M -266,500 Closed
Jane Street
437
Jane Street
New York
– -$9.18M -237,128 Closed
ECM
438
ExodusPoint Capital Management
New York
– -$3.11M -91,303 Closed
HF
439
HRT Financial
New York
– -$3.09M -90,915 Closed
Balyasny Asset Management
440
Balyasny Asset Management
Illinois
– -$2.84M -83,467 Closed
PEAK6
441
PEAK6
Illinois
– -$2.47M -63,749 Closed
SFI
442
Susquehanna Fundamental Investments
Pennsylvania
– -$2.06M -60,527 Closed
Tudor Investment Corp
443
Tudor Investment Corp
Connecticut
– -$1.98M -51,242 Closed
TI
444
Trexquant Investment
Connecticut
– -$1.32M -38,831 Closed
Walleye Trading
445
Walleye Trading
New York
– -$1.29M -33,453 Closed
TC
446
TwinBeech Capital
New York
– -$1.07M -31,578 Closed
Nomura Holdings
447
Nomura Holdings
Japan
– -$905K -26,596 Closed
AF
448
Avanza Fonder
Sweden
– -$866K -25,341 Closed
Wolverine Trading
449
Wolverine Trading
Illinois
– -$780K -21,081 Closed
FRM
450
Fox Run Management
Connecticut
– -$629K -18,473 Closed
16 17
18
19 20

CRSP Hedge Fund Activity: Q2 2025 in Review

433 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2025, worth a combined $3.52B — up 60% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new CRSP positions and 60 closed out — a net gain of 41 holders — while 127 added to existing stakes and 101 trimmed.

The largest buyer was BlackRock, adding an estimated $134M. The largest seller was UBS AM, cutting an estimated $38.2M.

  • 433 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2025, up from 396 in Q1 2025.
  • Funds reported $3.52B of CRISPR Therapeutics stock for Q2 2025, up 60% quarter-over-quarter.
  • 101 funds opened new CRISPR Therapeutics positions in Q2 2025 and 60 closed out, a net change of +41 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2025 was BlackRock, an estimated $134M added.
  • The largest CRISPR Therapeutics seller in Q2 2025 was UBS AM, an estimated $38.2M sold.

Based on aggregated 13F filings for Q2 2025.